Summary
Respiratory rate is a vital sign used to monitor the progression of illness both in hospitals and at home, particularly when dealing with at-risk patients. The continuous monitoring is key for patients with respiratory conditions (i.e. asthma), Chronic Obstructive Pulmonary Diseases (COPD) or pneumonia, with cardiovascular conditions, as well as elderly with comorbidities and prematurely born babies or babies with respiratory conditions.
SenseGuard respiratory monitoring device - is a decision support tool that assists practitioners in better monitoring patients with respiratory conditions like and at risks of deterioration. SenseGuard enables effective generation of alerts to clinical personnel, at the earliest moment following a change in patient’s status, at the hospital or at home. Due to its direct and high-resolution respiratory sensors, SenseGuard is able to continuously monitor pulmonary function on a breath-to-breath basis, unmatched by other technologies. SenseGuardTM can effectively monitor all at-risk patients.
NanoVation is an Israeli SME, founded in 2014, which develops and integrates nanomaterial-based sensors for medical applications and general purposes. Run by an experienced and multi-disciplinary team, NanoVation was granted several EU and non-EU projects, one of which awarded the 2018 Innovation Award by the European Commission. So far, NanoVation has raised and invested more than € 2.5M into the development of SenseGuard. To have it fully projected at a European and global level, NanoVation needs a further investment of €2.2M to complete product development and set up a solid EU value chain.
The proposed work in Phase 1 of the SME instrument fits into the company overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of SenseGuard and its market uptake.
SenseGuard respiratory monitoring device - is a decision support tool that assists practitioners in better monitoring patients with respiratory conditions like and at risks of deterioration. SenseGuard enables effective generation of alerts to clinical personnel, at the earliest moment following a change in patient’s status, at the hospital or at home. Due to its direct and high-resolution respiratory sensors, SenseGuard is able to continuously monitor pulmonary function on a breath-to-breath basis, unmatched by other technologies. SenseGuardTM can effectively monitor all at-risk patients.
NanoVation is an Israeli SME, founded in 2014, which develops and integrates nanomaterial-based sensors for medical applications and general purposes. Run by an experienced and multi-disciplinary team, NanoVation was granted several EU and non-EU projects, one of which awarded the 2018 Innovation Award by the European Commission. So far, NanoVation has raised and invested more than € 2.5M into the development of SenseGuard. To have it fully projected at a European and global level, NanoVation needs a further investment of €2.2M to complete product development and set up a solid EU value chain.
The proposed work in Phase 1 of the SME instrument fits into the company overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of SenseGuard and its market uptake.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/865082 |
| Start date: | 01-05-2019 |
| End date: | 30-09-2019 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Respiratory rate is a vital sign used to monitor the progression of illness both in hospitals and at home, particularly when dealing with at-risk patients. The continuous monitoring is key for patients with respiratory conditions (i.e. asthma), Chronic Obstructive Pulmonary Diseases (COPD) or pneumonia, with cardiovascular conditions, as well as elderly with comorbidities and prematurely born babies or babies with respiratory conditions.SenseGuard respiratory monitoring device - is a decision support tool that assists practitioners in better monitoring patients with respiratory conditions like and at risks of deterioration. SenseGuard enables effective generation of alerts to clinical personnel, at the earliest moment following a change in patient’s status, at the hospital or at home. Due to its direct and high-resolution respiratory sensors, SenseGuard is able to continuously monitor pulmonary function on a breath-to-breath basis, unmatched by other technologies. SenseGuardTM can effectively monitor all at-risk patients.
NanoVation is an Israeli SME, founded in 2014, which develops and integrates nanomaterial-based sensors for medical applications and general purposes. Run by an experienced and multi-disciplinary team, NanoVation was granted several EU and non-EU projects, one of which awarded the 2018 Innovation Award by the European Commission. So far, NanoVation has raised and invested more than € 2.5M into the development of SenseGuard. To have it fully projected at a European and global level, NanoVation needs a further investment of €2.2M to complete product development and set up a solid EU value chain.
The proposed work in Phase 1 of the SME instrument fits into the company overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of SenseGuard and its market uptake.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
